With your own knowledge and the help of the following document:

Document 1 (Title: Clinical Applications of Combined Antimicrobial Agents): Co-trimoxazole represents a widely utilized antimicrobial combination with distinctive pharmacological properties determining its clinical applications and safety considerations. Formulation analysis confirms this agent comprises a fixed combination of sulfamethoxazole and trimethoprim, typically in a 5:1 ratio, creating a synergistic antibacterial effect through sequential inhibition of bacterial folate synthesis. This combination demonstrates particular therapeutic efficacy against Toxoplasma gondii, establishing it as a mainstay treatment for toxoplasmosis across various clinical presentations including cerebral, ocular, and congenital infections. The synergistic mechanism involves sulfamethoxazole inhibition of dihydropteroate synthetase followed by trimethoprim inhibition of dihydrofolate reductase rather than dihydrofolate synthetase, creating a sequential blockade of distinct steps in the folate synthesis pathway. Adverse effect profiles include potentially severe cutaneous reactions ranging from mild rashes to life-threatening conditions including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell syndrome), particularly in specific risk groups including HIV-infected individuals. Significant drug interactions necessitate careful prescribing considerations, with concurrent methotrexate administration specifically contraindicated due to additive antifolate effects potentially resulting in severe bone marrow suppression and other toxicities. This interaction occurs through both agents affecting folate metabolism through different mechanisms, with trimethoprim inhibiting dihydrofolate reductase activity necessary for methotrexate clearance. The pharmacokinetic profile demonstrates good oral absorption and extensive tissue distribution, including cerebrospinal fluid penetration explaining its utility in central nervous system infections. These characteristics collectively inform appropriate clinical applications, dosing considerations, monitoring requirements, and contraindications for this widely utilized antimicrobial agent across diverse infectious disease scenarios.
Document 2 (Title: Nitroglycerin): Nitroglycerin is a vasodilatory drug used primarily to provide relief from anginal chest pain. Nitroglycerin has been FDA approved since 2000 and was first sold as a brand name agent. It is currently FDA approved for the acute relief of an attack or acute prophylaxis of angina pectoris secondary to coronary artery disease. Off label, non FDA approved uses include treatment for hypertensive urgency/emergency, coronary artery spasm, angina secondary to cocaine use, congestive heart failure (CHF), and chronic anal fissures. Along with hydralazine as a combination therapy, it is also indicated in patients with heart failure with reduced ejection in whom ACE inhibitors are contraindicated. Nitroglycerin is occasionally given to reduce radial spasms during coronary angiography through the radial approach. Nitroglycerin was first used in 1879 as a treatment for angina and since it has been part of management to relieve anginal chest pain.[1] Although nitroglycerin has a vasodilatory effect in both arteries and veins, the profound desired effects caused by nitroglycerin are primarily due to venodilation.[2] Venodilation causes pooling of blood within the venous system, reducing preload to the heart, which causes a decrease in cardiac work, reducing anginal symptoms secondary to demand ischemia. Arterial vasodilation will still occur and contribute to the relief of anginal symptoms.[3][4] Vasodilation of the coronary arteries will cause increased blood flow to the heart, increasing perfusion, but this effect remains minimal compared to the effects of venodilation.
Document 3 (Title: Infectious Complications and Management of Mammalian Bites): Mammalian bite wounds represent a significant cause of emergency department visits, with dog bites accounting for 80-90% of all reported cases. While immediate traumatic complications demand attention, infection risk represents the principal concern guiding therapeutic decision-making. The infectious risk varies substantially by biting species, wound characteristics, and host factors. Canine bite wounds typically demonstrate polymicrobial infections reflecting the dog's oral flora, with Pasteurella species (particularly P. canis), Staphylococcus, Streptococcus, Capnocytophaga canimorsus, and anaerobes including Bacteroides, Fusobacterium, and Porphyromonas predominating. Several factors influence infection risk, including wound location (hand bites carrying 3-4 fold higher risk), wound type (puncture wounds posing greater risk than lacerations), host immunocompetence, and time to medical attention. Wounds sustained during aggressive interactions, particularly those occurring while animals are feeding, demonstrate particularly high inoculation burdens. Initial management centers on thorough irrigation and debridement, with high-pressure irrigation (5-8 psi) using normal saline or tap water effectively reducing bacterial inoculum. Wound closure decisions require individualized assessment, with primary closure generally avoided for high-risk wounds including punctures, hand injuries, wounds with established infection, and those presenting beyond 12 hours post-injury. Prophylactic antibiotics are recommended for higher-risk wounds, with amoxicillin-clavulanic acid representing the consensus first-line agent due to its efficacy against both aerobic and anaerobic components of the typical polymicrobial inoculum, including beta-lactamase producing organisms. Alternative regimens for penicillin-allergic patients include trimethoprim-sulfamethoxazole or doxycycline plus clindamycin, though these combinations provide less reliable anaerobic coverage. Tetanus prophylaxis should be administered according to standard guidelines, with rabies risk assessment conducted for all mammalian bites.

Answer the following list question.
Question: Select the correct statement(s) regarding co-trimoxazole:
Options:
1. Is an association of sulfamethoxazole and trimethoprim
2. Is indicated in the treatment of toxoplasmosis
3. Trimethoprim is an inhibitor of dihydrofolate synthetase
4. Can cause severe skin disorders such as Lyell syndrome
5. Combination with methotrexate is contraindicated

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ‚Üê if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.